Bruce Feuchter

Securities & Corporate Counsel


Bruce Feuchter is a Shareholder of Stradling,Yocca, Carlson, and Rauth , in the Newport Beach office and a member of the firm’s Board of Directors at Stradling, where he has practiced since 1981. He specializes in corporate securities, corporate and general finance transactions and has represented investors, publicly held and privately held companies at various stages of their existence.



A highly sought after adviser and counselor, Bruce has developed a solid reputation for his ability to see early stage companies through to successful exits. He is well-known and respected in the emerging growth life science and technology community for representing TranS1 Inc., IntraLase Inc., Micro Therapeutics, Inc., Printrak International, Inc and The Right Start in their initial public offerings. In addition, he represented several companies including: LenSx Lasers in 2010 in their $744 million sale to Alcon, IntraLase in their $808 million sale to AMO and Micro Therapeutics in their $368 million sale to ev3.



Bruce also represents many companies in their venture financings and has represented venture capital funds in their investments with emerging growth companies. Representative early venture backed clients include: Tandem Diabetes, ReVision Optics, WaveTec Systems, Glumetrics, Vertos Medical, MindFrame, Altrua Medical, ReShape Medical, and Ivantis.

He serves on several industry and university committees including: Edwards Life Sciences Center for Advanced Cardiovascular Technology, OCTANe Leadership, University of California, Irvine Biomedical Engineering and the Paul Merage School of Business. 



Upon graduation from Hastings College of Law Bruce was awarded the Order of the Coif and inducted into the Thurston Honor Society.

Special Honors and Memberships


He is a member of the State Bar of California, the American Bar Association, and the Orange County Bar Association. He received special honors upon graduation in the Order of the Coif and the Thurston Honor Society from Hastings College of Law.

Representative Case List

  • IntraLase, Inc., $808 Million sale to Advanced Medical Optics
  • LenSx Lasers, Inc., $744 Million sale to Alcon
  • TranS1 Inc., IPO $94 Million
  • IntraLase IPO $92 Million
  • MindFrame, Inc., $75 Million sale to Covidien
  • Medical device venture financings ongoing on a regular basis eg Tandem Diabetes Care, Inc., $53 Million
  • ReVision Optics, Inc., $35 Million
  • WaveTec Vision Systems, Inc., $20 Million
Note: LaserACE® is not yet FDA approved or available in the United States. It is currently in clinical trials only in select areas outside of the United States.

Ace Vision Group, Inc.
39655 Eureka Dr, Newark, CA 94560
Telephone: 234-738-4074
234-738-4074

Ace Vision See Life NaturallyTM, LaserACE® and VisioLite® are registered trademarks of Ace Vision Group, Inc. All rights reserved. 2008-2020.